EGFR and non-small cell lung carcinoma: In the past decade, non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, such as exon 19 deletions and exon 21 L858R point mutations, have benefited from EGFR tyrosine kinase inhibitors (TKIs) [2, 3].